Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
287 participants
INTERVENTIONAL
2006-09-15
2008-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
NCT00394563
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA
NCT05462990
Safety and Efficacy of RHH646 for Knee Osteoarthritis
NCT05816395
A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
NCT01239017
Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis
NCT05248386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
RN624 (PF-04383119)
50 mcg/kg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RN624 (PF-04383119)
50 mcg/kg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant or lactating female subjects or subjects who do not agree to use an appropriate form of birth control throughout the study and for 3 months after completing the study
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BrookWood Internal Medicine
Birmingham, Alabama, United States
Radiant Research
Birmingham, Alabama, United States
Arizona Research Center, LLC
Phoenix, Arizona, United States
Imaging Centers of Anaheim
Anaheim, California, United States
Orange County Clinical Research
Anaheim, California, United States
Synergy Clinical Research Center
National City, California, United States
David M. Radin, MD
Stamford, Connecticut, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
Covance Clinical Research Unit, Inc
Daytona Beach, Florida, United States
Ocala Rheumatology Research Center
Ocala, Florida, United States
Tampa Medical Group, PA
Tampa, Florida, United States
Habana Hospital Pharmacy
Tampa, Florida, United States
Covance Clinical Research Unit, Inc. Honolulu
Honolulu, Hawaii, United States
Covance Boise
Boise, Idaho, United States
Northwest Indiana Center for Clinical Research
Merrillville, Indiana, United States
Office of David Neustadt, PSL
Louisville, Kentucky, United States
The Center for Rheumatology and Bone Research
Wheaton, Maryland, United States
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States
Center for Pharmaceutical Research, P.C.
Kansas City, Missouri, United States
Quality Clincal Research
Omaha, Nebraska, United States
Albuquerque Clinical Trials
Albuquerque, New Mexico, United States
AAIR Research Center
Rochester, New York, United States
Sports Medicine and Orthopaedics Center
Greensboro, North Carolina, United States
Pharmquest
Greensboro, North Carolina, United States
Pharmacotherapy Research Associates Incorporated
Zanesville, Ohio, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
New Orleans Center for Clinical Research
Knoxville, Tennessee, United States
Volunteer Research Group
Knoxville, Tennessee, United States
Office of Walter F. Chase, MD, PA
Austin, Texas, United States
Radiant Research - San Antonio
San Antonio, Texas, United States
Radiant Research San Antonio Northeast
San Antonio, Texas, United States
Rheumatology Associates of South Texas
San Antonio, Texas, United States
South Texas Radiology Imaging Center
San Antonio, Texas, United States
Pivotal Research
Midvale, Utah, United States
Charlottesville Medical Research
Charlottesville, Virginia, United States
Clinical Trials Northwest
Yakima, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011 Jun;19(6):639-46. doi: 10.1016/j.joca.2011.01.009. Epub 2011 Jan 18.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RN624-CL007
Identifier Type: OTHER
Identifier Source: secondary_id
A4091009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.